Skip to main content

Table 2 The results of univariate analyses using the Cox proportional hazard model

From: Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

Category, variable (reference)

Distant metastasis-free survival

Progression-free survival

Overall survival

 

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Age, > 71 (≤ 71)

1.21 (0.61–2.38)

0.57

1.09 (0.59–2.02)

0.77

2.31 (0.96–5.56)

0.05

Sex, Male (Female)

0.88 (0.39–1.96)

0.76

1.17 (0.53–2.5)

0.68

1.77 (0.59–5.27)

0.30

ECOG PS 1–2 (0)

2.08 (1.04–4.16)

0.03

1.96 (1.05–3.64)

0.03

1.67 (0.72–3.82)

0.22

Charlson comorbidity index, 2–4 (0–1)

0.74 (0.34–1.59)

0.44

0.90 (0.46–1.75)

0.77

1.30 (0.54–3.11)

0.55

Brinkman index, > 800 (≤ 800)

1.25 (0.63–2.48)

0.50

0.89 (0.47–1.65)

0.71

2.41 (1.03–5.60)

0.04

FEV1 (L), > 2.2 (≤ 2.2)

0.80 (0.40–1.61)

0.54

0.82 (0.43–1.54)

0.54

0.72 (0.31–1.71)

0.46

FEV1 (% of predicted), > 88 (≤ 88)

0.97 (0.48–1.95)

0.94

0.85 (0.45–1.60)

0.61

0.48 (0.20–1.17)

0.10

FEV1/FVC (%), > 71 (≤ 71)

1.13 (0.56–2.27)

0.72

1.06 (0.56–2.00)

0.83

0.68 (0.29–1.60)

0.38

Interstitial lung disease, No (Yes)

1.55 (0.36–6.55)

0.55

1.42 (0.33–6.00)

0.62

4.58 (0.98–21.34)

0.05

Diabetes mellitus, No (Yes)

1.46 (0.63–3.40)

0.37

1.31 (0.60–2.88)

0.48

2.00 (0.72–5.54)

0.17

COPD, No (Yes)

0.97 (0.46–2.06)

0.95

0.78 (0.38–1.61)

0.50

1.21 (0.51–2.87)

0.65

Pathology, Adenocarcinoma (Others)

0.54 (0.26–1.12)

0.10

0.73 (0.39–1.38)

0.34

0.30 (0.11–0.84)

0.02

PD-L1 tumour proportion score, ≥ 1% (< 1%)

0.63 (0.35–1.58)

0.33

0.83 (0.34–1.99)

0.68

0.65 (0.21–2.02)

0.46

Stage, IIA-IIIA (IIIB-VIA)

0.68 (0.34–1.35)

0.27

0.69 (0.37–1.28)

0.25

0.66 (0.28–1.52)

0.33

Chemotherapy, Yes (No)

0.42 (0.20–0.86)

0.01

0.46 (0.24–0.89)

0.02

0.40 (0.16–0.98)

0.04

PTV (cc), > 305 (≤ 305)

0.98 (0.49–1.96)

0.97

1.00 (0.54–1.86)

0.99

1.59 (0.69–3.66)

0.26

Dose coverage 90% of CTV (Gy), > 60.9 (≤ 60.9)

1.39 (0.70–2.73)

0.33

1.21 (0.65–2.25)

0.53

0.91 (0.39–2.07)

0.82

Dose coverage 90% of PTV (Gy), > 59.0 (≤ 59.0)

1.08 (0.55–2.13)

0.81

1.05 (0.56–1.94)

0.87

0.77 (0.33–1.79)

0.55

Lung V5 Gy (%), > 56.2 (≤ 56.2)

0.92 (0.47–1.81)

0.82

1.44 (0.77–2.69)

0.24

0.79 (0.34–1.81)

0.58

Lung V20 Gy (%), > 23.6 (≤ 23.6)

1.59 (0.80–3.14)

0.18

2.28 (1.21–4.29)

0.01

1.44 (0.63–3.32)

0.38

Overall treatment period of RT (days), 42–45 (46–59)

1.81 (0.90–3.63)

0.09

1.70 (0.91–3.18)

0.09

1.50 (0.64–3.48)

0.34

Response to RT, PR (SD or PD)

0.51 (0.23–1.12)

0.09

0.57 (0.29–1.14)

0.11

0.30 (0.10–0.89)

0.03

Durvalumab administration, Yes (No)

0.33 (0.16–0.69)

 < 0.01

0.32 (0.16–0.61)

 < 0.01

0.28 (0.11–0.74)

 < 0.01

Progression of irradiated sites, Yes (No)

1.85 (0.63–5.37)

0.25

-

-

1.54 (0.57–4.13)

0.38

Steroid administration, Yes (No)

1.72 (0.85–3.47)

0.12

1.26 (0.66–2.41)

0.46

2.26 (0.95–5.34)

0.06

Grade 2 or higher RP, Yes (No)

1.96 (0.96–4.03)

0.06

1.52 (0.78–2.95)

0.20

2.14 (0.92–5.01)

0.07

Grade 3 or higher RP, Yes (No)

1.40 (0.42–4.64)

0.58

1.65 (0.58–4.72)

0.34

2.21 (0.64–7.52)

0.20

  1. ECOG Eastern Cooperative Oncology Group, PS performance status, FEC forced expiratory volume, FVC forced vital capacity, COPD chronic obstructive pulmonary disease, PD-L1 programmed death-ligand 1, PTV planning target volume, CTV clinical target volume, Lung Vn Gy percentage of total lung volume exceeding n Gy, RT radiotherapy, PR partial response, SD stable disease, PD progressive disease, RP radiation pneumonitis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us